Skip to content
10-K

Annual Report

ADIAL PHARMACEUTICALS, INC. ADIL

0001213900-26-024175

← back to feed
Filed
Mar 5, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 4, 2026 1.43M sh
Shares Diluted FY 2025 · Dec 31, 2025 668.63K sh
Shares Diluted restated FY 2025 · Dec 31, 2024 194.06K sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$6.49M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$6.92M
Cash And Equivalents FY 2025 · Dec 31, 2025 $5.88M
Cash And Equivalents FY 2025 · Dec 31, 2024 $3.75M
Stockholders Equity FY 2025 · Dec 31, 2025 $5.28M
Stockholders Equity FY 2025 · Dec 31, 2024 $4.07M
Stockholders Equity FY 2025 · Dec 31, 2023 $4.08M
Current Liabilities FY 2025 · Dec 31, 2025 $1.4M
Current Liabilities FY 2025 · Dec 31, 2024 $975.86K
Total Liabilities FY 2025 · Dec 31, 2025 $1.4M
Total Liabilities FY 2025 · Dec 31, 2024 $975.86K
Current Assets FY 2025 · Dec 31, 2025 $6.18M
Current Assets FY 2025 · Dec 31, 2024 $4.06M
Total Assets FY 2025 · Dec 31, 2025 $6.67M
Total Assets FY 2025 · Dec 31, 2024 $5.04M
Eps Diluted FY 2025 · Dec 31, 2025 −$11.93
Eps Diluted restated FY 2025 · Dec 31, 2024 −$68.01
Eps Basic FY 2025 · Dec 31, 2025 −$11.93
Eps Basic restated FY 2025 · Dec 31, 2024 −$68.01
Sga Expense FY 2025 · Dec 31, 2025 $5.18M
Sga Expense FY 2025 · Dec 31, 2024 $5.06M
Rd Expense FY 2025 · Dec 31, 2025 $2.62M
Rd Expense FY 2025 · Dec 31, 2024 $3.23M
Net Income FY 2025 · Dec 31, 2025 −$7.98M
Net Income FY 2025 · Dec 31, 2024 −$13.2M
Operating Income FY 2025 · Dec 31, 2025 −$7.8M
Operating Income FY 2025 · Dec 31, 2024 −$8.28M